The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol
about
Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysisEffects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms.What is new with the beta2-agonists: issues in the management of asthma.The role of pharmacogenomics in improving the management of asthmaClinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.Can certain genotypes predispose to poor asthma control in children? A pharmacogenetic study of 9 candidate genes in children with difficult asthma.Asthma pharmacogenetics and the development of genetic profiles for personalized medicinePharmacogenomics of long-acting β2-agonists.Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterolA simple and rapid genotyping assay for simultaneous detection of two ADRB2 allelic variants using fluorescence resonance energy transfer probes and melting curve analysis.Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Non-corticosteroid therapy for the long-term control of asthma.Pharmacogenetics of the response to beta 2 agonist drugs: a systematic overview of the field.Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids.beta-Adrenergic receptor polymorphisms: relationship to the beta-agonist controversy and clinical implications.Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.Clinical consequences of ADRbeta2 polymorphisms.beta-Adrenergic receptor polymorphisms and response to salmeterol.Pharmacogenetic response to albuterol among asthmatics.Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxidePharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicineRecent advances in pediatric asthma treatment.Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long-acting β-agonists and asthma.Emerging role of long acting muscarinic antagonists for asthmaPharmacogenetics of beta2 adrenergic receptor agonists in asthma management.Do genetic polymorphisms alter patient response to inhaled bronchodilators?Think the impossible: beta-blockers for treating asthma.Formoterol fumarate inhalation solution (Perforomist) for COPD.Reply: Adverse effects of long-acting beta-agonists on airway hyperresponsiveness.Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.Adverse effects of long-acting beta-agonists on airway hyperresponsiveness.Long-acting beta2 agonists and inhaled corticosteroids in asthma.Pharmacogenetics of asthma controller treatment.The effect of beta2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma.Tailored second-line therapy in asthmatic children with the Arg(16) genotype.Effects of the inverse alpha-agonist doxazosin in allergic rhinitis.
P2860
Q26781071-1FDDDCAD-9615-40AD-B622-410E3B1D4C60Q30413107-F8C01E76-2F6C-455D-A9BE-399BECFBD17CQ33213762-A23714E9-7D59-460F-AC28-1FEA6E31F089Q33669054-0CC0892A-7111-4D3F-AAA0-D840934AFB87Q33792699-F8BD6985-B423-41F7-9797-8EDF67B2DD80Q34038869-553FE6FA-D651-4739-B1EB-7440E77C8C4EQ34662042-F4526F5F-A679-46F8-B4F2-160A286D0B00Q35076452-A41DBBC8-8CFE-4211-8E98-527E8C75247EQ35734012-344AA8F4-96E1-4BDF-995C-87059A56C6C8Q36237969-339A42F0-BCAF-4B6A-AC6D-E79231AE84EEQ36579644-C961F7C4-A58F-4CD8-A85F-5CD5FF07F330Q36704483-8E2880C7-406C-43A9-872C-C25EF1068036Q36892408-F3775C86-FD78-4BC7-B27C-1E7DB40CB1F0Q36916911-C9C83629-1386-486C-B1E8-0288423E8415Q36918110-9282C891-8274-4B33-8BB1-CC029318F3BEQ36924300-8AEDB3F7-C9F0-4086-9BE5-8D0CEA1CEFDDQ37013051-B8454592-E132-46C2-AC90-E29FD3A66509Q37062771-8C32558B-96E3-45D3-B2CC-0775CD987DE2Q37096063-29B630E3-D676-4EF4-B0D0-0D027C5E614BQ37144386-58E27645-C519-48A1-94E5-B7105B590A31Q37157889-B19103C6-55F7-44DA-B004-BE30C03615EEQ37183249-0A28E44C-3955-4279-B75D-44C1973CDCB6Q37425660-80A3F2E7-4AAC-4184-A9EE-460B6E0E85A1Q37566530-07941FE2-AC4D-42DC-BA72-BB0906C1E84BQ37600573-AE3238E6-A5D0-4BE5-8F3B-1CEA5D909AECQ37755012-C1FE0CAC-E970-42B8-876F-F94C466AF5E0Q37835874-9DB462F1-8A47-47A2-94BD-9D6FAD453D26Q38093655-7EF077B8-4FC2-4D76-8929-C23289D85B40Q38196942-DDF1E3C8-98C1-4F62-9F1E-183D9D9DEA6FQ38237766-56E5DED5-7D94-4B43-B408-F2E1887D7FB1Q39297594-F669E876-C8B7-425B-9AB8-1C2AA05F2E70Q39317855-D6B0BCA9-8105-474C-B509-BD3A61D6938DQ42912763-FC7C35F0-D6BD-424B-A013-F030C98FDF9FQ43243148-9A53D773-F39A-4E42-A9ED-FFE2A8C3ED47Q43824202-D10CDD19-08F8-4617-81D5-7484350C560AQ45744943-033A05A6-4937-4F0D-B4CF-DB9AAD7F062CQ46107352-5C80BB7A-D83B-43E4-90FC-AB4094A5226CQ46892035-1C91B63C-93D0-41B9-AAB2-2AC7870A78B0Q50898958-DA4F19BB-624C-4617-838E-123EC01FD5ECQ51558388-2EC1E85A-7F1B-4372-8313-5C1FC861D511
P2860
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@ast
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@en
type
label
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@ast
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@en
prefLabel
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@ast
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@en
P2093
P2860
P1476
The arginine-16 beta2-adrenoce ...... with formoterol and salmeterol
@en
P2093
Brian J Lipworth
Daniel K C Lee
John J Lima
P2860
P356
10.1046/J.1365-2125.2003.01955.X
P407
P577
2004-01-01T00:00:00Z